Results 281 to 290 of about 44,321 (338)

Remarkable Prolongation of Irreversible APTT and Non‐Significant Hemorrhage: A Rare High Titer of FVIII Inhibitor Case Report and Literature Review

Journal of Clinical Laboratory Analysis, Volume 40, Issue 2, January 2026.
Patient with a bladder cancer history presented was diagnosed with Acquired hemophilia A (AHA) according to imaging findings and laboratory tests. The parameters returned to normal after treatment of methylprednisolone and cyclophosphamide. With the recurrence of AHA, the patient was finally confirmed to have liver metastases.
Ke‐Han Zhang, Song‐Song Lu, Pei‐Liang Gao, Xue‐Ying Fu, Gui‐Ying Dong   +4 more
wiley   +1 more source

Bispecific Antibodies for Lymphoid Malignancy Treatment. [PDF]

Cancers (Basel)
Bisio M, Legato L, Fasano F, Benevolo Savelli C, Boccomini C, Nicolosi M, Santambrogio E, Freilone R, Novo M, Botto B.   +9 more
europepmc   +1 more source

Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma

The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Elranatamab, a bispecific antibody targeting B‐cell maturation antigen, is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). An exposure–safety analysis was conducted using the data from patients with RRMM across four clinical studies, MagnetisMM‐1, 2, 3, and 9 (NCT03269136, NCT04798586, NCT04649359, and NCT05014412)
Pooneh Soltantabar, Jennifer Hibma, Diane Wang, Umberto Conte, Anne Hickman, Mohamed Elmeliegy   +5 more
wiley   +1 more source

Characteristics of second primary malignancies following bispecific antibodies therapy. [PDF]

J Immunother Cancer
Liang X, Luo B, Lin B, Liu D, Guo J, Lu W, Tian S, Cai Z, Zhou X, Jin Z, Li T, Chen K, Zhou H, Wang L.   +13 more
europepmc   +1 more source

Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance

Journal of Extracellular Vesicles, Volume 15, Issue 1, January 2026.
Non‐invasive biomarkers are needed to further personalize EGFR tyrosine kinase inhibitor (EGFR TKI) osimertinib treatment in non‐small cell lung cancer (NSCLC) patients. By analysing the proteome of extracellular vesicles (EVs) isolated from an osimertinib resistant NSCLC cell line and from serum of patients given osimertinib in second line within the ...
Albano Cáceres‐Verschae, Petra Hååg, Sofia Joelsson, Per Hydbring, Bo Franzén, Ákos Végvári, Inger Johanne Z. Eide, Nupur Agarwal, Siddharth Sourabh Sahu, Fredrik Stridfeldt, Luigi De Petris, Apurba Dev, Simon Ekman, Odd Terje Brustugun, Rolf Lewensohn, Kristina Viktorsson   +15 more
wiley   +1 more source

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy

Hematological Oncology, Volume 44, Issue 1, January 2026.
Pier Luigi Zinzani, Giulia Dell’Omo, Letizia Fusco, Ilaria Peduto, Carlotta Galeone, Federica Cavallo, Giuseppe Gritti   +6 more
wiley   +1 more source

Melanoma: Pathogenesis and Targeted Therapy

MedComm, Volume 7, Issue 1, January 2026.
The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu, Jie Liu, Zeming Mo, Bin Wang, Yaotiao Deng, Yu Jiang   +5 more
wiley   +1 more source

Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects

MedComm, Volume 7, Issue 1, January 2026.
The management of cancer and tissue regeneration remains a substantial challenge to global health. Organoids, which are stem cell‐derived three‐dimensional multicellular structures, are revolutionizing biomedical research. Therefore, this review highlights their applications in cancer research and regenerative medicine, while discussing current ...
Ruiyang Li, Yuezhou Wu, Zhu'anzhen Zheng, Fengjin Zhou, Ke Xu, Jiacan Su   +5 more
wiley   +1 more source

Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study. [PDF]

Blood Cancer J
Chalopin T, Cellerin E, Demarquette H, Pieragostini A, Sonntag C, Jaquet C, De Wyngaert Z, Rumpler A, Roussel M, Labouré G, Morel V, Vincent L, Salle V, Cazaubiel T, Bobin A, Schavgoulidze A, Corre J, Leleu X, Manier S.   +18 more
europepmc   +1 more source